Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium, Inc. (NASDAQ: EQ) presented promising results from its EQUATE study on itolizumab for treating high-risk acute graft-versus-host disease (aGVHD) at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. Key findings include a 72% overall survival rate at 12 months and significant progression-free survival. At Day 29, 52% of patients achieved a complete response (CR), with 64% overall response rate (ORR). Remarkably, responders reduced corticosteroid use by 73% at Day 29 and 96% at six months, suggesting itolizumab's potential as an effective first-line therapy.
Equillium has initiated the EQUATOR study, a pivotal Phase 3 clinical trial assessing itolizumab as a first-line treatment for acute graft-versus-host disease (aGVHD). The study aims to enroll up to 200 patients globally, with primary endpoints focusing on complete response at Day 29. The previous EQUATE study demonstrated promising results, with a complete response rate of 52% in high-risk patients. Equillium has also received fast track and orphan drug designations from the FDA for itolizumab.
Equillium, Inc. (Nasdaq: EQ) has appointed Dr. Barbara Troupin to its Board of Directors, where she will serve on the Nominating and Corporate Governance Committee. Dr. Troupin brings extensive experience in clinical development and regulatory affairs, crucial as Equillium prepares for its Phase 3 study for acute graft-versus-host disease. Her previous roles include senior vice president at Myokardia and chief medical officer positions at ERX Pharmaceuticals, Aquinox, and Apricus Biosciences. This leadership addition may enhance Equillium's capabilities in novel therapeutics targeting severe autoimmune disorders.
Equillium has acquired Bioniz Therapeutics, enhancing its immunology pipeline with two first-in-class clinical assets and a proprietary discovery platform. The acquisition, valued at 5,699,492 shares of common stock (approximately 19.3% of Equillium’s capital), aims to drive significant growth through advanced therapeutic candidates for autoimmune and inflammatory diseases. Key products include BNZ-1, progressing to Phase 2 trials for alopecia areata, and BNZ-2, set to enter Phase 1 for celiac disease. Equillium retains exclusive rights to all Bioniz products, reinforcing its strategic position in the market.
Equillium, Inc. (NASDAQ: EQ), a clinical-stage biotechnology company, announced updates for its conference participation. The company will hold a virtual fireside chat at the SVB Leerink Virtual Global Healthcare Conference on February 17, 2022, at 2:20 pm ET, with a live webcast available on its website. Additionally, the dates for the American Society of Transplantation and Cellular Therapy conference have been rescheduled to April 23-26, 2022, and will be held both virtually and in-person in Salt Lake City. Equillium is focused on developing itolizumab for severe autoimmune and inflammatory disorders.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, announced its participation in the SVB Leerink Virtual Global Healthcare Conference from February 14-18, 2022. Chief Executive Officer Bruce Steel and Chief Scientific Officer Steve Connelly will present an overview of the company and its clinical programs on February 16 at 2:20 PM ET. Attendees can join via a live webcast on Equillium's website, with an archived version available for 90 days. Equillium focuses on developing itolizumab for severe autoimmune disorders with significant unmet needs.
Equillium, Inc. (NASDAQ: EQ) announced the acceptance of three abstracts for presentation at the Transplantation & Cellular Meetings from February 2-6, 2022. The abstracts focus on the safety and efficacy of itolizumab in treating acute graft-versus-host disease (aGVHD), highlighting promising outcomes in severe cases. Key findings include a novel targeted therapy's rapid effects on T-cell activity and its role in regulating T effector cell migration. The research underscores the importance of itolizumab for patients with high-risk aGVHD, with no approved first-line treatments currently available.
Equillium, Inc. (Nasdaq: EQ) announced that its CEO, Bruce Steel, will present at the H.C. Wainwright Virtual BioConnect Conference on January 10, 2022, at 7:00 am EST. The presentation will cover key topics, including itolizumab’s mechanism of action and topline data from the Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD). Regulatory feedback relevant to a pivotal aGVHD study and the EQUALISE study in systemic lupus erythematosus will also be discussed. A webcast will be available on the company’s website for 90 days.
Equillium announced promising findings from a study published in the Journal of Clinical Investigation that highlights the role of the CD6-ALCAM pathway in lupus nephritis (LN). The research included over 1,000 patients and suggests that soluble ALCAM could serve as a biomarker for LN activity. The data supports the development of itolizumab, a monoclonal antibody targeting this pathway, which is currently being evaluated in the EQUALISE clinical study. Encouraging results show itolizumab's potential to reduce disease activity in SLE patients with renal involvement.
Equillium, Inc. (NASDAQ: EQ) announced the successful completion of the Phase 1b EQUIP study of itolizumab, aimed at treating uncontrolled asthma. The study met its primary objective of safety and tolerability, showing that itolizumab effectively reduced cell surface CD6 levels at Day 85 post-treatment. Adverse events were mostly mild to moderate, with transient lymphopenia in 79% of subjects. Although asthma control improved, the small sample size limited significant observations. Equillium plans to focus on pivotal studies for acute graft-versus-host disease and lupus nephritis.